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Abstract
OBJECTIVES: The ACURATE TATM system is a self-expanding transcatheter heart valve system designed for transapical access which has
been proven to be safe and effective in the controlled setting of clinical trials. The SAVI-1 and SAVI-2 registries aimed to assess whether
these promising outcomes can be translated into all-comers clinical routine.
METHODS: From November 2011 to 2012 (SAVI-1), and November 2013 to 2014 (SAVI-2), a total of 500 patients were enrolled in the
prospective, all-comers, multicentre, multinational SAVI registries. Patients were treated according to the standard of care at their respect-
ive hospitals. We report and compare 30-day and 1-year clinical outcomes between SAVI-1 and -2.
RESULTS: Patients were 80.8 ± 6.1 years old, the mean logistic EuroSCORE-I was 23.4 ± 14.3%. Valves were deployed under rapid pacing in
71.3% of the procedures in SAVI-1, and in 3.6% in SAVI-2. There was no relevant difference in clinical and echocardiographic outcomes be-
tween SAVI-1 and SAVI-2. Overall mortality at 30 days and 1 year was 6.8% and 19.9%, the stroke rate was 2.2% and 3.7%, respectively;
10.2% of patients had received a permanent pacemaker, and no transcatheter valve-related complications after discharge were observed.
Paravalvular leakage >_2+ was reported in 1.9% of the patients at the early follow-up, and in 2.6% at the 1-year follow-up.
CONCLUSIONS: The SAVI-registries have confirmed that transapical implantation using the ACURATE TATM device is safe and effective in
an all-comers setting with low complication rates and stable performance outcomes at short-term and 1 year; outcomes were similar be-
tween SAVI-1 and -2.
ClinicalTrials.gov: NCT02663375
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INTRODUCTION
Almost a decade ago, the first transcatheter heart valves gained
CE approval. Since then, transcatheter aortic valve implantation
(TAVI) has become a widely adopted technique. In Germany, a
20-fold increase in TAVI procedures was observed from 2008 to
2014, and TAVI numbers started to exceed those of surgical aor-
tic valve replacement in 2013 [1, 2].
Meanwhile, second-generation devices have been developed
to address limitations observed in first-generation devices,
amongst them the ACURATE TATM transapical transcatheter heart
valve system (Symetis SA, Ecublens, Switzerland), which gained
CE approval in 2011. The most characteristic aspect of this sys-
tem is its ease of use, mainly driven by intuitive positioning with
tactile feedback as well as the anatomical (commissure to com-
missure) positioning and placement of the device [3, 4].
Safety and performance of the ACURATE TATM system have
been tested in 40 patients enrolled in the First-in-Men study and
in 50 patients enrolled in the Pilot study, also called ‘TA90 cohort’
[3, 5]. To determine whether the outcomes obtained in controlled
study settings can be translated to clinical routine, the first 250
commercially treated patients were enrolled in the ‘Symetis
ACURATE TATM Valve Implantation’ registry (SAVI-1) [5, 6]. One
year later, SAVI-2 was started to continue to collect and monitor
ongoing safety and efficacy data on the commercial use of the
product. This report combines the 1-year outcomes of both
registries.
MATERIALS AND METHODS
Study design and population
SAVI-1 and SAVI-2 are prospective, all-comers, multicentre regis-
tries conducted in 17 (SAVI-1) and 26 (SAVI-2) centres in Europe
and Argentina, but predominantly in Germany. The study design
and population of SAVI-1 has been described previously [6].
SAVI-2 has a similar design. Treatment and follow-up were ac-
cording to the standard of care at the respective hospital. Clinical
follow-up, including echocardiographic assessment, was sched-
uled at discharge or after 7 days, whichever was earlier; at 30
days, a telephone follow-up was conducted (for SAVI-1, clinical
and echocardiographic follow-up was scheduled at 30 days). The
last registry follow-up was at 12 months, including clinical and
(voluntary) echocardiographic assessments. Each registry was
scheduled to enrol 250 patients.
The inclusion criteria were broad to allow for an all-comers
population and included all patients with severe aortic stenosis,
native annulus diameter from >_21 up to <_27 mm, informed con-
sent signature, and willingness to return for follow-up visits.
Excluded were patients not eligible for TAVI with ACURATE TATM
as per the instructions for use. The registry was approved by the
respective ethic committees.
Study device
The ACURATE TATM valve has been previously described [4, 5]. In
brief, it is a self-expanding nitinol prosthesis with porcine leaflets.
Stabilizer arches serve to orientate the prosthesis within the as-
cending aorta during the deployment phase and avoid its tilting.
The diabolo-shape facilitates self-alignment and self-centering of
the prosthesis, and a PET skirt contributes to preventing paravalv-
ular leaks (PVL). The prosthesis is available in three different sizes,
S, M and L. The delivery system has a crossing profile of 33
F. Commissures of the prosthesis can be placed adjacent to the
patients commissure and thus the valve is placed in a truely ana-
tomical manner.
Endpoints and definitions
The primary endpoint of SAVI-1 was the rate of major cardiac
and cerebrovascular events (MACCE) at 30 days and 1 year,
defined as composite of death, myocardial infarction, reinterven-
tion, and stroke. The primary endpoint of SAVI-2 was the inci-
dence of all-cause mortality at 30 days. Secondary end-points
according to the Valvular Academic Research Consortium-2
(VARC-2) guidelines [7] were: mortality, stroke, myocardial infarc-
tion, bleeding complications, acute kidney injury, vascular com-
plications, conduction disturbances and arrhythmias, and other
TAVI-related complications (i.e. valve-in-valve, conversion to
open heart, coronary obstruction, unplanned use of cardiopul-
monary bypass, ventricular septal perforation, mitral valve appar-
atus damage/dysfunction, cardiac tamponade, endocarditis, valve
thrombosis, valve migration/embolization) at 30 days and 1 year.
Functional improvement from baseline was assessed via the New
York Heart Association (NYHA) functional classification at the
30-day and 1-year follow-ups. We intend to compare safety and
performance outcomes between SAVI-1 and -2.
Statistical analysis
No formal sample size calculation was conducted. Data were
analysed according to the Intention-to-Treat population, which
included all patients in whom an implant was attempted. Patients
who received a prosthesis other than the study valve (e.g. conver-
sion to open heart, valve-in-valve) were excluded from echocar-
diographic follow-up, but included in safety assessments. Data
are presented using descriptive statistical methods. For quantita-
tive variables, means and standard deviations (SD) were calcu-
lated, and for categorical data absolute and relative frequencies.
When appropriate, 95% CIs were calculated. Event estimates
were calculated using the Kaplan–Meier method; the log-rank
test was used to compare overall mortality. Cox proportional
hazards regression analysis was used to explore the association
between SAVI-1 and SAVI-2. Data analysis was performed using
SAS V9.3 (SAS Institute Cary, NC, USA).
RESULTS
Five hundred patients have been enrolled in the SAVI-1 and
SAVI-2 registries. The patient flow is displayed in Figure 1. In
SAVI-1, approximately 70% of centres were first-time users, and
15 (58%) new centres were included in SAVI-2. No centre en-
rolled more than 15% of patients. The centre list is provided in
the Supplementary Material, Table S1.
Baseline and procedural characteristics are displayed in Table 1.
Risk scores were slightly lower in the SAVI-1 compared to the
SAVI-2 cohort (Logistic EuroSCORE-I of 22.3 ± 12.7% vs
24.7 ± 15.7%).
Of all 500 procedures, in SAVI-1 and SAVI-2, implantation of
the ACURATE TA valve was successful in 489 (97.8%) patients. In
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SAVI-1, 3 conversions to open-heart surgery occurred (1 intra-
procedural event when the device was pulled into the left ven-
tricle during delivery system withdrawal, 1 on post-procedure
day 1 for severe aortic regurgitation, and another on day 7 for
severe aortic regurgitation after tilted valve deployment). Two
valve-in-valve procedures using another commercially available
transcatheter heart valve were performed for severe aortic regur-
gitation. In SAVI-2, no conversion to open heart occurred, but 6
valve-in-valve procedures (of these, 1 was associated with coron-
ary obstruction, 2 with valve migration 1 with coronary obstruc-
tion and valve migration), 1 unplanned use of cardiopulmonary
bypass and 1 mitral valve apparatus damage/dysfunction. Both
patients with coronary obstruction and valve-in-valve procedure
were diagnosed with porcelain aorta at baseline.
Echocardiographic parameters were similar between the regis-
tries, with slightly less paravalvular leakage >_2+ at 1 year in SAVI-2
(0.8% vs 4.1%) (Table 2, Fig. 2). The NYHA classification improved
from 93.5% of patients in NYHA class III/IV at baseline to 13.0%
at 1 year (Fig. 3, Supplementary Material, Table S2).
Relevant safety outcomes are displayed in Table 3, and
additional outcomes in Supplementary Material, Table S3.
Figure 1: Patient flow diagram.
Table 1: Baseline and procedural characteristics
SAVI-1 SAVI-2 Total
n = 250 n = 250 n = 500
Baseline
Age [years] 80.9 ± 6.3 80.7 ± 5.9 80.8 ± 6.1
Male 126 (50.8)a 104 (41.6) 230 (46.2)
Logistic EuroSCORE-I [%] 22.3 ± 12.7 24.7 ± 15.7 23.4 ± 14.3
STS Score [%] 8.0 ± 5.9 11.9 ± 10.0 9.8 ± 8.3
Procedure
Prior balloon valvuloplasty 240 (97.2)b 218 (87.2) 458 (92.2)
Device sizes used
S 84 (33.6) 68 (27.2) 152 (30.4)
M 93 (37.2) 109 (43.6) 202 (40.4)
L 73 (29.2) 73 (29.2) 146 (29.2)
Deployment under rapid pacing 176 (71.3)b 9 (3.6) 185 (37.0)
Post-dilatation 97 (38.8) 110 (44.0) 207 (41.4)
Procedure
Successful implant 245 (98.0) 241 (96.4) 489 (97.8)
Valve-in-valve procedure 2 (0.8) 6 (2.4) 8 (1.6)
Conversion to surgery 3 (1.2) 0 3 (0.6)
Data are presented as mean ± SD or n (%). NA: not assessed. aunknown
in two patients, bunknown in three patients.
Table 2: Echocardiographic assessments
SAVI-1 SAVI-2 Total




0.71 ± 0.21 0.75 ± 0.31 0.73 ± 0.26
Mean gradient
[mmHg]
43.1 ± 17.4 42.2 ± 14.9 42.7 ± 16.2
n = 219 n = 203 n = 422
30 days Discharge/7-daysa
Effective orifice area 1.44 ± 0.45 1.48 ± 0.43 1.45 ± 0.44
Mean gradient [mmHg] 12.4 ± 5.8 12.5 ± 6.0 12.5 ± 5.9
Paravalvular leak
0: non/trace 159 (72.6) 141 (69.5) 300 (71.1)
1+: mild 55 (25.1) 59 (29.1) 114 (27.0)
2+: moderate 5 (2.3) 3 (1.5) 8 (1.9)
3+: moderate/severe 0 0 0
4+: severe 0 0 0
1 year n = 148 n = 126 n = 274
Effective orifice area 1.51 ± 0.38 1.57 ± 0.40 1.54 ± 0.39
Mean gradient 12.9 ± 5.3 11.1 ± 4.4 12.1 ± 5.0
Paravalvular leak
0: non/trace 111 (75.0) 80 (63.5) 191 (69.7)
1+: mild 31 (20.9) 45 (35.7) 76 (27.7)
2+: moderate 5 (3.4) 1 (0.8) 6 (2.2)
3+: moderate/severe 1 (0.7) 0 1 (0.4)
4+: severe 0 0 0
Data are presented as mean ± SD or n (%). Not all measurements were
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Notably, only SAVI-2 outcomes were categorized by VARC-2 cri-
teria. In general, outcomes were similar between SAVI-1
and SAVI-2. Mortality at 30 days was 6.4% [95% CI: 3.3–9.4]
for SAVI-1 and 7.2% [95% CI:3.9–10.4] for SAVI-2, and at 1 year
18.9% [95% CI:13.9–23.7] and 20.8% [95% CI:15.6–25.8] respect-
ively, P = 0.64 (Fig. 4).
DISCUSSION
The real-world SAVI registries with 500 enrolled patients show
very good safety and performance outcomes in patients treated
with the ACURATE TATM system. Outcomes across the SAVI-1
and SAVI-2 registries and the ‘TA90’ First-in-man and pilot stud-
ies are consistent, e.g. moderate or severe PVL <3.5%, 10% per-
manent pacemaker implantation, and 20% 1-year mortality [3,
5]. This is remarkable as the ‘TA 90’ cohort were first-time users,
as well as approximately 70% of centres in SAVI-1 [6], and speaks
for the ease of use of the device. There was a difference in the
rate of conversion to open heart between SAVI-1 and -2, though.
This could have been a coincidental finding, but could also re-
flect the fact that, in general, complication management had im-
proved. Similarly, during the same time period, the GARY registry
observed an improvement in technical procedural complications
[8]. Notably, the number of valve-in-valve procedures was higher
in SAVI-2 (2.4% vs 0.8%)—eventually, patients who would have
been converted in the early experience had received a valve-in-
valve procedure in SAVI-2. Furthermore, the difference between
SAVI-1 and -2 observed for rapid pacing probably reflects the
increasing confidence in this technique.
Figure 2: Echocardiographic parameters over time (SAVI-1 and SAVI-2). (A) Aortic valve haemodynamics, measured as mean gradient and effective orifice area (EOA),
and (B) percentage of patients with paravalvular leakage. Values remained stable between early follow-up at discharge/30 days and 1 year.
Figure 3: New York Heart Association (NYHA) classification at baseline and fol-
low-up (SAVI-1 and SAVI-2).
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Reasons for low complication rates and ease of use of the de-
vice have previously been reported: (i) re-sheathability, (ii) top-
down implantation technique compressing the native leaflets
and capturing them in the waist of the device, hence reducing
the risk of paravalvular leakage and potentially also reducing the
risk of coronary occlusion, (iii) stabilization arches allowing a co-
axial self-alignment of the valve and stent commissure alignment
during fluoroscopy, hence avoiding a stent-post in front of the
coronary ostia and potentially easing later interventional access
to the coronaries, (iv) the upper crown allows supra-annular an-
choring, tactile feedback and stable positioning, (v) the waist con-
forms to the native annulus, (vi) the lower crown allows for
minimal stent protrusion into the left ventricle and hence (in
combination with the low radial force needed due to the ana-
tomic shape of the valve) reduces the risk of conduction system
interference with subsequent pacemaker implantation, and (vii)
the PET skirt acts as a seal to prevent PVL [4–6, 9].
Regarding valve design, there could be a concern that the two-
step deployment and the higher need for post-dilatation
compared to balloon-expanding valves [10] might lead to a
higher stroke rate. With the limitation of site-reported data and
the lack of differentiation between minor and major stroke, we
did not observe a high stroke rate in the SAVI-registries. This ob-
servation is confirmed by a transcranial doppler ultrasound
study, comparing the frequency and pattern of high-intensity
transient signals (HITs) in 22 patients receiving either the transap-
ical ACURATE TATM or the balloon-expandable SAPIEN XT valve
(Edwards Lifesciences LLC, Irvine, CA, USA), which found similar
outcomes for both devices [11].
Kempfert et al. [6] compared early SAVI-1 results with those of
the FRANCE-2 and SENTINEL registries using the CoreValve
(Medtronic Inc., Minneapolis, MN, USA) and SAPIEN/SAPIEN XT
prosthesis. Even though they included 75% transfemoral cases,
early mortality was comparable, the leakage rate extremely
promising, and the pacemaker rate within the range of the
SAPIEN system and superior to the CoreValve system.
Furthermore, SAVI-1 and -2 outcomes compare well to those of
a recent review of transapical second-generation transcatheter
heart valves [12], a recently published report of the JUPITER regis-
try using the JenaValve (JenaValve Technology GmbH, Munich,
Germany) [13], and the transapical cohort of the GARY registry
[14]. Thirty-day mortality in our series was 6.8% compared to
8.9%, 11.1% and 7.7% (in-hospital mortality), and pacemaker
were implanted in 10.2% compared to 12.1%, 14.4% and 11.3%,
respectively. Bailout situation (valve-in-valve implantations and
conversion to open heart) occurred in 2.2% of our series, com-
pared to 5.0% in the JUPITER study and 2.0% (valve-in-valve pro-
cedures only) in the GARY registry.
Moderate to severe PVL at 30 days occurred in only 1.9%
(2.6% at 1 year) of our cases. Accordingly, in a single-centre
series, the ACURATE TATM valve had the lowest PVL-rate of
next-generation transapical valves [15], and significantly less PVL
than the transfemoral CoreValve prosthesis [16]. Overall,
echocardiographic parameters (effective orifice area and mean
gradient) and NYHA class remained stable between 30 days
and 1 year.
Figure 4: All-cause mortality per Kaplan–Meier estimate.
Table 3: Kaplan–Meier estimates of relevant clinical outcomes at 30 days and 1 year
SAVI-1a SAVI-2 Total HR
30 days
Mortality 16 (6.4) [3.3–9.4] 18 (7.2) [3.9–10.4] 34 (6.8) [4.6–9.0] 1.12 (0.57:2.2)
Cardiovascular 5 (2.0) [0.3–3.8] 9 (3.6) [1.3–5.9] 14 (2.8) [1.4–4.3] 1.80 (0.60:5.37)
Non-cardiovascular 11 (4.5) [1.9–7.0] 9 (3.7) [1.3–6.0] 20 (4.1) [2.3–5.8] 0.82 (0.34:2.00)
Strokeb 7 (2.9) [0.8–4.9] 4 (1.6) [0.0–3.2] 11 (2.2) [0.9–3.5] 0.57 (0.17:1.95)
Myocardial infarction 1 (0.4) [0.0–2.0] 1 (0.4) [0.0–1.2] 2 (0.4) [0.0–1.0] 1.00 (0.06:15.99)
AKI stage 3 NA 7 (2.8) [0.7–4.9] – NA
Other TAVI-related complications post-discharge 0 0 0 NA
New onset of atrial fibrillation/atrial flutter NA 20 (8.2) [4.7–11.5] – NA
Permanent pacemaker 25 (10.2) [6.3–14.0] 25 (10.2) [6.3–13.9] 50 (10.2) [7.5–12.9] 1.01 (0.58:1.76)
1 year n = 241 n = 243 n = 484
Mortality 47 (18.9) [13.9–23.7] 51 (20.8) [15.6–25.8] 98 (19.9) [16.3–23.3] 1.10 (0.74:1.64)
Cardiovascular 15 (6.4) [3.2–9.4] 19 (8.2) [4.5–11.6] 34 (7.3) [4.9–9.6] 1.31 (0.66:2.57)
Non-cardiovascular 32 (13.2) [8.9–17.4] 32 (13.8) [9.2–18.1] 64 (13.5) [10.4–16.5] 1.02 (0.62:1.66)
Stroke 10 (4.2) [1.6–6.7] 7 (3.2) [0.8–5.5] 17 (3.7) [1.9–5.4] 0.72 (0.27:1.89)
Other TAVI-related complications post-discharge 0 0 0 NA
Data are presented as n (%) [95% CI], and HR. AKI-acute kidney injury, HR-hazard ratio, calculated using the Cox proportional hazards regression analysis, NA-
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Notably, even though the registries enrolled between 2011 and
2014, and many centres were first-time users, the pacemaker,
stroke and PVL rates comply to the ‘future targets for optimal
quality centres’ as published in a recent state-of-the-art review
which postulated the following limits: new pacemaker <10%, major
stroke <2% and moderate to severe PVL <5% [17].
These results confirm that the ACURATE TATM valve adds an-
other valuable option to the TAVI armamentarium. Currently, it
is the only commercially available self-expandable valve for
transapical access. Due to its unique features, this valve might be
particularly useful in (i) patients with low coronary ostia as the
tissue will be pulled away from the ostia during implantation [6],
(ii) patients with massive calcification, as well as an absence of
calcification [5], or even in pure aortic regurgitation [18], (iii) due
to its low pacemaker and PVL rates and implantability without
rapid pacing—in patients with poor left ventricular ejection frac-
tion, (iv) centres with little experience as the valve is easy to im-
plant and resheathing and repositioning are possible until final
release [4–6], and (v) low-volume centres as they ideally restrict
themselves to two valve types to allow adequate device experi-
ence and therefore should select a valve type that can serve the
transfemoral and transapical approach.
Undoubtedly, with the adaption of smaller introducer systems,
transfemoral nowadays is the most common access route.
Exemplary in Germany, the numbers of transapical cases have re-
mained constant over the years while there has been a massive
increase in transfemoral ones [2]. This has probably led to an
even more severely diseased patient population for transapical
cases, especially related to peripheral artery disease.
Correspondingly, SAVI-2 patients had numerically higher risk
scores than SAVI-1 patients. Nevertheless, 30-day mortality is
nearly identical between both registries and there is no statistic-
ally significant difference in 1-year mortality, even though the
Kaplan–Meier curves start to diverge after 3 months, which might
be indicative of a more severely diseased patient population.
Though the majority of cases are transfemoral nowadays [2],
the transapical approach is still relevant. When transfemoral ac-
cess is not possible, it is the access of choice, as reported in a
recently conducted survey [19]. It has not only the advantage
of a short distance to the annulus, resulting in precise control
of the device, but also avoids crossing of the aortic arch, which
is especially helpful in severely calcified anatomy, and can
ultimately be applied in almost all patients [10]. Furthermore,
there is a development towards devices with smaller transapical
delivery systems. Recently, the combination of ACURATE neoTM
with a 22F outer diameter transapical delivery system has been
successfully tested [4] and a CE approval trial is currently
enrolling.
Limitations of the SAVI registries are the ones inherent to regis-
tries, such as self-reporting of events. However, risk of under-
reporting was minimized due to the application of yes/no ques-
tions for safety endpoints. Furthermore, data were not
monitored, nor adjudicated, no core laboratory was used, and
SAVI-1 did not include VARC recommendations [7]. As—due to
the nature of a registry—echocardiographic assessment was op-
tional, only slightly more than 50% returned for echocardio-
graphic assessment at 1 year. Furthermore, only rudimentary
baseline information was available (e.g. preimplant pacemaker
rate was not assessed). Baseline parameters would have been im-
portant to gain a better understanding of how the population
changed between SAVI-1 and SAVI-2. Lastly, future research
should include long-term follow-up.
CONCLUSION
The SAVI-registries have shown that transapical implantation
using the ACURATE TATM device is safe and effective in an all-
comers setting with low mortality, pacemaker and PVL rates, and
stable haemodynamics throughout follow-up. There was no rele-
vant difference in outcomes between SAVI-1 and -2.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
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